CA88337V1004
© Newsfile
12.12.2025
TLT
LISTED
TSX
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
News Preview
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, has commen...
Themefolio
Profiler
Peergroup
© Newsfile
24.11.2025
TLT
LISTED
TSX
Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
News Preview
Toronto, Ontario--(Newsfile Corp. - November 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has en...
Themefolio
Profiler
Peergroup
© Newsfile
17.11.2025
TLT
LISTED
TSX
Theralase(R) Investor Conference Call Reminder
News Preview
Theralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demonstrating 64.3% Complete ResponseToronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sou...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Newsfile
10.11.2025
TLT
LISTED
TSX
Theralase(R) Releases 3Q2025 Financial Statements
News Preview
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
03.11.2025
TLT
LISTED
TSX
Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug
News Preview
Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to share a scien...
Themefolio
Profiler
Peergroup
© Newsfile
24.09.2025
TLT
LISTED
TSX
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
News Preview
Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, announced today the peer-revie...
Themefolio
Profiler
Peergroup
© Newsfile
29.08.2025
TLT
LISTED
TSX
Theralase(R) Extends Warrants
News Preview
Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce that...
Themefolio
Profiler
Peergroup
© Newsfile
26.08.2025
TLT
LISTED
TSX
Theralase(R) Releases 2Q2025 Financial Statements
News Preview
Toronto, Ontario--(Newsfile Corp. - August 26, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited...
Themefolio
Profiler
Peergroup
© Newsfile
28.07.2025
TLT
LISTED
TSX
Theralase(R) Closes Non-Brokered Private Placement
News Preview
Toronto, Ontario--(Newsfile Corp. - July 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it...
Themefolio
Profiler
Peergroup
© Newsfile
27.06.2025
TLT
LISTED
TSX
Theralase(R) Extends Warrants
News Preview
Toronto, Ontario--(Newsfile Corp. - June 27, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce that the Com...
Themefolio
Profiler
Peergroup
© Newsfile
17.06.2025
TLT
LISTED
TSX
Theralase(R) Closes Non-Brokered Private Placement
News Preview
Toronto, Ontario--(Newsfile Corp. - June 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it...
Themefolio
Profiler
Peergroup
© Newsfile
12.06.2025
TLT
LISTED
TSX
Theralase Completes Annual General and Special Meeting
News Preview
Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce the su...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
05.06.2025
TLT
LISTED
TSX
Theralase Annual General Meeting
News Preview
Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is reminding shareholders of its Annual G...
Themefolio
Profiler
Peergroup
© Newsfile
30.05.2025
TLT
LISTED
TSX
Theralase(R) 1Q2025 Financial Statements
News Preview
Toronto, Ontario--(Newsfile Corp. - May 30, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited inter...
Themefolio
Profiler
Peergroup
© Newsfile
29.05.2025
TLT
LISTED
TSX
CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025
News Preview
Radiation-Activated Rutherrin(R) Versus Radiation Alone in Preclinical Cancer Models to be Presented at ASTRO 2025This Press Release removes references to preclinical data that has not yet been presented.Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or t...
Themefolio
Profiler
Peergroup
© Newsfile
28.05.2025
TLT
LISTED
TSX
Theralase to Present Groundbreaking Research at ASTRO 2025
News Preview
Radiation-Activated Rutherrin(R) Shown to Be 100 Times More Effective Than Radiation Alone in Preclinical Cancer ModelsToronto, Ontario--(Newsfile Corp. - May 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and d...
Themefolio
Profiler
Peergroup
© Newsfile
20.05.2025
TLT
LISTED
TSX
Theralase Provides Corporate Update
News Preview
Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and ef...
Themefolio
Profiler
Peergroup
© Newsfile
05.05.2025
TLT
LISTED
TSX
Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
News Preview
Toronto, Ontario--(Newsfile Corp. - May 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of small molecules and their formulations, able to be activated by light, radiation, sound and/or other drugs, intende...
Themefolio
Profiler
Peergroup
© Newsfile
28.04.2025
TLT
LISTED
TSX
Theralase Discovers New Mechanism of Action of Lead Drug
News Preview
Theralase(R) Has Discovered a New Mechanism of Action in Its War on Cancer; Specifically, Ruvidar's(TM) Ability to Inhibit DeUbiquitinating Enzymes, an Important Class of Enzymes Which Have Been Linked to Numerous Cancers and Neurogenerative DiseasesToronto, Ontario--(Newsfile Corp. - April 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT)...
Themefolio
Profiler
Peergroup
© Newsfile
14.04.2025
TLT
LISTED
TSX
Theralase(R) Closes Non-Brokered Private Placement
News Preview
Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and...
Themefolio
Profiler
Peergroup
© Newsfile
10.04.2025
TLT
LISTED
TSX
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
News Preview
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model.Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...
Themefolio
Profiler
Peergroup
© Newsfile
07.04.2025
TLT
LISTED
TSX
Ruvidar Demonstrates 7 Year Complete Response
News Preview
Patient Diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ Treated Once with Light-Activated Ruvidar(TM) Demonstrates 7 Year Complete ResponseToronto, Ontario--(Newsfile Corp. - April 7, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clini...
Themefolio
Profiler
Peergroup
© Newsfile
24.03.2025
TLT
LISTED
TSX
Ruvidar Effective in the Treatment of Herpes
News Preview
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus the standard of care treatments Acyclovir and Abreva in a preclinical animal model.Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Themefolio
Profiler
Peergroup
© Newsfile
12.03.2025
TLT
LISTED
TSX
Theralase(R) Releases 2024 Annual Financial Statements
News Preview
Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and...
Themefolio
Profiler
Peergroup
© Newsfile
11.03.2025
TLT
LISTED
TSX
Theralase(R) Closes Non-Brokered Private Placement
News Preview
Toronto, Ontario--(Newsfile Corp. - March 11, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and...
Themefolio
Profiler
Peergroup
© Newsfile
10.03.2025
TLT
LISTED
TSX
Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients
News Preview
Parkinson's Patients Have Improved Motor and Non-Motor Function After Treatment with Theralase(R) Cool Laser TherapyToronto, Ontario--(Newsfile Corp. - March 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development...
Themefolio
Profiler
Peergroup
© Newsfile
25.02.2025
TLT
LISTED
TSX
Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
News Preview
Rutherrin(R), when combined with a common diabetic drug and radiation, was able to effectively destroy Non-Hodgkin's Lymphoma in an animal model.Toronto, Ontario--(Newsfile Corp. - February 25, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedi...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
13.02.2025
TLT
LISTED
TSX
CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
News Preview
This Press Release updates numerical list in reference sectionTheralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ACCESS Newswire / February 13, 2025 / Theralase® Technologies Inc. ("Theralase...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
12.02.2025
TLT
LISTED
TSX
Theralase(R) Demonstrates Effective Treatment of Herpes
News Preview
Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ACCESS Newswire / February 12, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTF...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
10.02.2025
TLT
LISTED
TSX
Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses
News Preview
University of Manitoba independent research verifies that RuvidarTM is more effective than acyclovir in the inactivation of Herpes Simplex Viruses post infection. TORONTO, ON / ACCESS Newswire / February 10, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage ph...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2025
TLT
LISTED
TSX
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
News Preview
TORONTO, ON / ACCESS Newswire / January 27, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.12.2024
TLT
LISTED
TSX
Theralase(R) Launches Three New Clinical Study Sites in USA
News Preview
Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®'s bladder cancer treatment TORONTO, ON / ACCESSWIRE / December 9, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OT...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
05.12.2024
TLT
LISTED
TSX
Theralase(R) Launches New Clinical Study Site in Canada
News Preview
St. Joseph's Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®'s Anti-Cancer Therapy for the treatment of bladder cancerTORONTO, ON / ACCESSWIRE / December 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinica...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.11.2024
TLT
LISTED
TSX
Theralase(R) Release’s 3Q2024 Financial Statements
News Preview
TORONTO, ON / ACCESSWIRE / November 27, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecules and their formulations, intended for th...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
15.11.2024
TLT
LISTED
TSX
Theralase(R) Closes Non-Brokered Private Placement
News Preview
TORONTO, ON / ACCESSWIRE / November 15, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
12.11.2024
TLT
LISTED
TSX
Theralase(R) Extends Warrants
News Preview
TORONTO, ON / ACCESSWIRE / November 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.10.2024
TLT
LISTED
TSX
Theralase(R) Provides Update on Bladder Cancer Clinical Study
News Preview
TORONTO, ON / ACCESSWIRE / October 7, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the s...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
24.09.2024
TLT
LISTED
TSX
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
News Preview
TORONTO, ON / ACCESSWIRE / September 24, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for th...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.09.2024
TLT
LISTED
TSX
Theralase(R) Extends Warrants
News Preview
TORONTO, ON / ACCESSWIRE / September 19, 2024 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
